- Preface
- Contributors
- Symbols and Abbreviations
- Classes of recommendations and levels of evidence
- Amendments and Updates
- Chapter 1.1 Hypertension
- Chapter 1.2 Dyslipidaemia
- Chapter 1.3 Metabolic syndrome and diabetes
- Chapter 1.4 Thrombosis
- Chapter 2.1 Acute coronary syndrome: STEMI and NSTEMI
- Chapter 2.2 Chronic stable angina
- Chapter 2.3 Coronary artery spasm and microvascular angina
- Chapter 2.4 Takotsubo syndrome
- Chapter 3.1 Heart failure
- Chapter 3.2 Heart transplantation
- Chapter 4.1 Atrial fibrillation
- Chapter 4.2 Supraventricular (narrow complex) tachycardias
- Chapter 4.3 Ventricular arrhythmias
- Chapter 4.4 Bradyarrhythmias
- Chapter 4.5 Syncope
- Chapter 5.1 Valvular heart disease
- Chapter 5.2 Myocarditis and pericardial syndromes
- Chapter 5.3 Cardiomyopathy
- Chapter 5.4 Pulmonary hypertension
- Chapter 6.1 Kidney disease
- Chapter 6.2 Pregnancy and lactation
- Chapter 6.3 Liver disease
- Chapter 7.1 Major drug interactions
- Chapter 8.1 Cardiovascular drugs—from A to Z
- Chapter 9.1 Non-cardiac drugs affecting the heart—from A to Z
- Index
(p. 251) Syncope
- Chapter:
- (p. 251) Syncope
- Author(s):
Ricardo Ruiz-Granell
- DOI:
- 10.1093/med/9780198759935.003.0015_update_001
Update:
The section on Management of neurally mediated syncope has been revised
Syncope results from sudden, transient, global cerebral hypoperfusion. Neurally mediated syncope, orthostatic hypotension, arrhythmic and cardiac syncope, and steal syndromes are the main pathophysiological forms of syncope. This chapter focuses on the treatment of neurally mediated syncope and orthostatic syncope, since other forms of syncope are reviewed elsewhere. In neurally mediated and orthostatic syncope, patient education and non-pharmacological measures are the mainstay of treatment, although benefits of pharmacological treatment are not so evident.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- Preface
- Contributors
- Symbols and Abbreviations
- Classes of recommendations and levels of evidence
- Amendments and Updates
- Chapter 1.1 Hypertension
- Chapter 1.2 Dyslipidaemia
- Chapter 1.3 Metabolic syndrome and diabetes
- Chapter 1.4 Thrombosis
- Chapter 2.1 Acute coronary syndrome: STEMI and NSTEMI
- Chapter 2.2 Chronic stable angina
- Chapter 2.3 Coronary artery spasm and microvascular angina
- Chapter 2.4 Takotsubo syndrome
- Chapter 3.1 Heart failure
- Chapter 3.2 Heart transplantation
- Chapter 4.1 Atrial fibrillation
- Chapter 4.2 Supraventricular (narrow complex) tachycardias
- Chapter 4.3 Ventricular arrhythmias
- Chapter 4.4 Bradyarrhythmias
- Chapter 4.5 Syncope
- Chapter 5.1 Valvular heart disease
- Chapter 5.2 Myocarditis and pericardial syndromes
- Chapter 5.3 Cardiomyopathy
- Chapter 5.4 Pulmonary hypertension
- Chapter 6.1 Kidney disease
- Chapter 6.2 Pregnancy and lactation
- Chapter 6.3 Liver disease
- Chapter 7.1 Major drug interactions
- Chapter 8.1 Cardiovascular drugs—from A to Z
- Chapter 9.1 Non-cardiac drugs affecting the heart—from A to Z
- Index